HeartBeam, Inc. (BEAT) Stock: Price, Forecast & Analyst Target
HeartBeam, Inc. (BEAT) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.3089 (-9.25%), as of the Nov 19, 2026 trading session; market cap $19.6M.
Educational signal · not a buy or sell recommendation · How to read this
HeartBeam, Inc. · BEAT · NASDAQ
HeartBeam, Inc. is a medical technology company focused on providing telemedicine solutions for cardiac disease detection and monitoring. Their primary product is a credit card-sized electrocardiogram machine coupled with cloud-based diagnostic software.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · HeartBeam (BEAT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Sound; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 5 of the last 8 reports
- Altman Z -13.53 · Piotroski F 2
Holding back: weak fundamentals, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 32 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 30 | Weak | |
| 30 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3089 | |
| Change on the day | -9.25% | |
| Market capitalisation | $19.6M | — |
| Shares traded on the day | 861.0K |
Price & events
Other perspectives
Council score for HeartBeam (BEAT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
0 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read date unavailable · not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is HeartBeam (BEAT), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. HeartBeam, Inc. (BEAT) is listed on NASDAQ. It employs 16 people. The market values it at $19.6M.
What do the latest results show for HeartBeam (BEAT)?
Short answer · as of
Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $0 | -$3M | -$0.05 (diluted) |
| Q2 FY2026 | $0 | -$5M | -$0.10 (diluted) |
| Q1 FY2026 | $0 | -$5M | -$0.12 (diluted) |
| Q4 FY2025 | $0 | -$5M | -$0.16 (diluted) |
What are the financial strengths and risks for HeartBeam (BEAT)?
Short answer
What is holding it back is weak fundamentals, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -13.53 · Piotroski F 2. Trailing ratios: current ratio 3.66.
Data-derived red flags
- Listing risk — at $0.3089 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -13.53 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at HeartBeam (BEAT)?
Short answer · as of
Current published price targets run low $2.00 · high $2.00 · consensus $2.00 · median $2.00 against a quoted price of $0.3089 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How is HeartBeam scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $2.00 – $2.00
- Consensus target
- $2.00
- Median target
- $2.00
Consensus record · Captured .
Measured against a quoted price of $0.3089 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 2, 2026
- Transactions
- 17
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 0
- Other transactions
- 17
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BEAT in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BEAT in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about HeartBeam (BEAT)?
Common Questions About BEAT
These answers are editorial: 1 of these 9 answers is drawn from the BEAT research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for BEAT?
BEAT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. HeartBeam, Inc. is a medical technology company focused on providing telemedicine solutions for cardiac disease detection and monitoring.
Is BEAT a good stock to buy?
Stock Expert AI does not rate BEAT buy, sell or hold. HeartBeam, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the BEAT stock price today?
The last price recorded for HeartBeam, Inc. (BEAT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BEAT price target?
The analyst consensus price target for HeartBeam, Inc. (BEAT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What does HeartBeam, Inc. do?
HeartBeam, Inc. is a medical technology company focused on developing and commercializing telemedicine solutions for the detection and monitoring of cardiac disease outside of traditional healthcare settings. Their core product is a credit card-sized electrocardiogram (ECG) machine that patients can use at home to record their heart activity.
What are the key factors to evaluate for BEAT?
HeartBeam, Inc. (BEAT) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Addresses the rapidly growing field of remote patient monitoring. Not financial advice.
How frequently does BEAT data refresh on this page?
BEAT's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven BEAT's recent stock price performance?
HeartBeam, Inc. (BEAT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative telemedicine solutions for cardiac care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BEAT overvalued or undervalued right now?
HeartBeam, Inc. (BEAT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 10 from Financial Modeling Prep (FMP), 4 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com